A multi country, non-interventional prospective cohort study among patients with human growth hormone (hGH) treatments under routine clinical care
Not Applicable
Recruiting
- Conditions
- Growth hormone deficiency
- Registration Number
- JPRN-UMIN000050880
- Lead Sponsor
- Pfizer Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 2225
Inclusion Criteria
Not provided
Exclusion Criteria
1. Participation in any interventional clinical trials at the time of enrollment.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To estimate incidence rates (IRs) of safety events of interest among patients on Genotropin, other daily hGH treatments, and Ngenla. To describe and compare effectiveness of Genotropin, other daily hGH treatments, and Ngenla.
- Secondary Outcome Measures
Name Time Method